Identification of monoclonal antibody variants involved in aggregate formation - Part 1: Charge variants
- PMID: 33221370
- DOI: 10.1016/j.ejpb.2020.10.020
Identification of monoclonal antibody variants involved in aggregate formation - Part 1: Charge variants
Abstract
Biopharmaceutical products contain conformational and chemical variants, that are typically well characterized regarding identity and activity. However, little is known about their self-interaction propensity and tendency to unfold, which are critical characteristics for drug stability and safety. This study aimed to separate and compare charge variants of a monoclonal antibody (mAb) and to identify aggregation prone species. We show a semi-preparative cation exchange method, that we developed to separate the individual acidic and basic variants from the naïve mAb. Additionally, we demonstrate, that the yield and purity of the fractionated charge species, extracted by that method, were sufficient for subsequent analysis of aggregate content, conformation stability and self-interaction. Our analysis revealed a differently behaving acidic variant and confirmed its increased aggregation propensity by molecular modeling. During a stability study, the potentially aggregation prone charge variant posed a limited risk to the drug substance (DS). We are the first to look at the stability of single charge variants of biopharmaceuticals, and thus present manufacturers and regulatory authorities with a method to enhance drug safety.
Keywords: Differential scanning fluorimetry; FPLC; Light scattering; Protein aggregation; Protein stability; mAb charge variants.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Role of Charge Heterogeneity on Physical Stability of Monoclonal Antibody Biotherapeutic Products.Pharm Res. 2024 Jul;41(7):1443-1454. doi: 10.1007/s11095-024-03730-1. Epub 2024 Jun 28. Pharm Res. 2024. PMID: 38951451
-
Identification of monoclonal antibody variants involved in aggregate formation - Part 2: Hydrophobicity variants.Eur J Pharm Biopharm. 2021 Mar;160:134-142. doi: 10.1016/j.ejpb.2021.01.006. Epub 2021 Jan 30. Eur J Pharm Biopharm. 2021. PMID: 33524536
-
Characterization of the aggregation propensity of charge variants of recombinant human growth hormone.Int J Pharm. 2022 Jun 10;621:121760. doi: 10.1016/j.ijpharm.2022.121760. Epub 2022 Apr 30. Int J Pharm. 2022. PMID: 35504429
-
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.MAbs. 2012 Sep-Oct;4(5):578-85. doi: 10.4161/mabs.21328. Epub 2012 Jul 23. MAbs. 2012. PMID: 22820257 Free PMC article. Review.
-
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants.Antibodies (Basel). 2022 Nov 20;11(4):73. doi: 10.3390/antib11040073. Antibodies (Basel). 2022. PMID: 36412839 Free PMC article. Review.
Cited by
-
Harnessing the potential of machine learning for advancing "Quality by Design" in biomanufacturing.MAbs. 2022 Jan-Dec;14(1):2013593. doi: 10.1080/19420862.2021.2013593. MAbs. 2022. PMID: 35000555 Free PMC article. Review.
-
Process- and Product-Related Foulants in Virus Filtration.Bioengineering (Basel). 2022 Apr 4;9(4):155. doi: 10.3390/bioengineering9040155. Bioengineering (Basel). 2022. PMID: 35447715 Free PMC article. Review.
-
Role of Charge Heterogeneity on Physical Stability of Monoclonal Antibody Biotherapeutic Products.Pharm Res. 2024 Jul;41(7):1443-1454. doi: 10.1007/s11095-024-03730-1. Epub 2024 Jun 28. Pharm Res. 2024. PMID: 38951451
-
LC-MS Characterization and Stability Assessment Elucidate Correlation Between Charge Variant Composition and Degradation of Monoclonal Antibody Therapeutics.AAPS J. 2024 Apr 3;26(3):42. doi: 10.1208/s12248-024-00915-9. AAPS J. 2024. PMID: 38570351
-
Antibody association in solution: cluster distributions and mechanisms.MAbs. 2024 Jan-Dec;16(1):2339582. doi: 10.1080/19420862.2024.2339582. Epub 2024 Apr 26. MAbs. 2024. PMID: 38666507 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources